Predicting chronic leukaemias from assesment of complete peripheral blood counts

Journal of International Medical Research

Volumn 34, Issue 6, 2006, Pages 640-647

  Hayran, M ^a   Koca, E ^a   Haznedaroglu, I C ^a   Unsal, I ^b   Durgun, B ^c   Guvenc, F ^c   Ozturk, B ^c   Ratip, S ^b   Ozcebe, O I ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ACIBADEM HOSPITAL   (Turkey)

^c Novartis Inc   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ARTICLE; BASOPHIL; BLOOD CELL COUNT; CELL MATURATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; EOSINOPHIL; FEMALE; HISTOPATHOLOGY; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL; PREDICTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT;

EID: 33846466077     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000603400609     Document Type: Article

References (21)

1. O'Brien S, Tefferi A, Valent P: Chronic myelogenous leukemia and myeloproliferative disease. Hematology (Am Soc Hematol Educ Program) 2004: 146-162.
2. Hehlmann R, Berger U, Hochhaus A: Chronic myeloid leukemia a model for oncology. Ann Hematol 2005; 84: 487-497.
3. Randolph TR: Chronic myelocytic leukemia - Part I: History. clinical presentation, and molecular biology. Clin Lab Sci 2005; 18: 38-48.
4. Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, et al: Staging of chronic myeloid leukemia in the imatinib era: an evoluation of the World Health Organization proposal. Canser 2006; 106: 1306-1315.
5. Koca E, Hazhedaroglu IC: Imatinib mesylate and the management of chronic myeloid leukemia (CML). Turk J Haematol 2005; 22: 161-172.
6. Stephens JM, Gramegna P, Laskin B, Botteman MF, Pashos CL: Chronic lymphocytic leukemia: economic burden and quality of life: literature review. Am J Ther 2005; 12: 460-466.
7. Herishanu Y, Polliack A: Chronic lymphocytic leukemia: a review of some new aspects of the biology, factors influencing prognosis and therapeutic option. Transfus Apher Sci 2005; 32: 85-97.
8. Byrd JC, Stilgenbauer S, Flinn IW: Chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2004: 163-183.
9. Hamblin TJ: Chronic lymphocytic leukaemia: clinical translations of biological features. Curr Top Microbiol Immunol 2005; 294: 165-185.
10. Kantarjian MM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S, et al: Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003; 101: 97-100.
11. Saglio G, Cilloni D, Rancati F, Boano L: Glivec and CML: a lucky date. J Biol Regul Homeost Agents 2004; 18: 246-251.
12. Pfirrmann M, Hasford J: A simulation study using validated prognostic factors to assess expected lonq-term survival. Methods Inf Med 2005; 44: 577-583.
13. National Cancer Institute: Report of the Leukemia, Lymphoma, and Myeloma Progress Review Group. Bethesda, MD: National Cancer Institute, 2001.
14. Abbott BL: Advances in the diagnosis and treatment of chronic lymphocytic leukemia. Hematol Oncol 2005, 23: 34-40.
15. Marti GE, Rawstron AC, Ghia P, Hillmen P, Houlston RS, Kay N, et al: Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 2005; 130: 325-332.
16. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
17. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, et al: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-1937.
18. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, et al: Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99: 3547-3553.
19. Gratwohl A: Does early stem-cell transplantation have a role in chronic myeloid leukaemia? For the proposal. Lancet Oncol 2005; 6: 721-722.
20. Schwarz J, Mikulenkova D, Cermakova M, Polanska V, Michalova K, Marinov I, et al: Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers. Neoplasma 2006; 53: 219-225.
21. Abbott BL: Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist 2006; 11: 21-30.